Chronic graft versus host disease (GVHD) of lung is associated with higher transplant related morbidity and mortality after allogeneic hematopoeitic cell transplant (HCT). Risk factors for lung GVHD are not yet fully elucidated in detail. We attempted to identify clinical risk factors for lung GVHD after allogeneic HCT based on single center experience. 401 patients were transplanted between year 2000 and 2007 at the Princess Margaret Hospital, Toronto, Canada. 280 (70%) and 121 (30%) patients received peripheral blood stem cell (PBSC) and bone marrow (BM) as a source of stem cells, respectively. Monitoring with pulmonary function tests (PFT) were performed prior to transplant, at day 180, then annually. PFT was also performed when indicated clinically. CT scan of lung was performed to confirm the diagnosis of lung GVHD and to exclude other infectious causes. Bronchoscopic lavage was performed to exclude potential infectious cause if needed. Potential clinical risk factors for lung GVHD were examined including conditioning, age, gender, source of stem cell, diagnosis, disease status and previous episode of acute GVHD. With median follow up of 1,122 days, 68 patients (16.9%) had a diagnosis of chronic GVHD of lung with median onset of 349 days (range 71-1,880 days; 95% CI [299-398 days]), 53(78%) of whom patients received myeloablative conditioning. Fifty one(75%) patients received matched sibling donor transplant versus 17(25%) patients received unrelated donor. Overall survival rates remained similar in both cohorts. In the univariate analyses, other clinical risk factors were not associated with the risk of chronic GVHD of lung: conditioning (p = 0.9), age with cut off of 60 years (p = 0.4), donor type (p = 0.5), grade II-IV acute GVHD (p = 0.7), grade III-IV acute GVHD(p = 0.4), development of CMV reactivation (p = 0.6). However, incidence of chronic GVHD lung was significantly higher in the group receiving PBSC (13.8± 2.4% at 1 year; 23.0±3.2% at 2 years) than in those receiving BM (6.8±2.5% at 1 year; 16±3.8% at 2 years; p = 0.02, hazard ratio 1.937, 95%CI [1.100-3.410]). Multivariate analyses also confirmed PBSC transplantation as an independent risk factor for chronic GVHD of lung (p = 0.005, hazard ratio 2.359, 95%CI [1.290-4.314]). The use of PBSC increases the risk of lung GVHD compared to the use of BM for allogeneic HCT. Closer monitoring is warranted to detect lung GVHD early after PBSCT.
Read full abstract